FALLYPRIDE
Parkinson Disease
Ruijin HospitalSmall moleculePhase 3Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 65/ 100
Competitive context
165 Active assets in the Parkinson Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ropinirole Titan Pharmaceuticals | Phase 4 | BBB |
Benserazide Ankara Ataturk Sanatorium Training and Research Hospital | Phase 4 | BBB |
Ongentys Bial - Portela C S.A. | Phase 4 | BBB |
Ctc-501 First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
LEVODOPA McMaster University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
FALLYPRIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →